Research Use Only — Confirm to Continue

OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.

By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.

Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use
OptimalDosages

Semaglutide Dosage & Reconstitution

GLP-1 receptor agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.

1Set Up Your Mix

2.5 mg/mL · 2500 mcg/mL
All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — SemaglutideYour Answer

—
20Draw To This Line
0.2That's This Many mL
10Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 20
5 mg ÷ 2 mL = 2.5 mg/mL  →  0.5 mg ÷ 2.5 mg/mL = 0.2 mL  →  × 100 = 20 units—
Looks good. Draw to 20 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 10 doses.

2Week-By-Week Plan — Semaglutide

Approved-label escalation
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Initiation (wk 1–4) 0.25 mg once weekly 0.1 mL 10 u 20 doses
Escalation (wk 5–8) 0.5 mg once weekly 0.2 mL 20 u 10 doses
Escalation (wk 9–12) 1 mg once weekly 0.4 mL 40 u 5 doses
Escalation (wk 13–16) 1.7 mg once weekly 0.68 mL 68 u 2 doses
Trial maintenance 2.4 mg once weekly 0.96 mL 96 u 2 doses
Weeks until the top dose
16 weeks
Peptide used getting there
13.8 mg
Vials you'll need
3 × 5 mg
Once you're at the top dose
9.6 mg / 4 wk · 1.92 vials
Where this plan came from
A published dosing schedule
Where this came from: STEP 1 trial protocol and the approved 2.4 mg escalation schedule. Steps exist to manage gastrointestinal tolerability. Trial protocols hold or step back down when a dose is not tolerated rather than pushing forward on schedule.

3Common Doses — Semaglutide

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Weeks 1–4 0.25 mg once weekly 0.1 mL 10 u 4 1 mg
Weeks 5–8 0.5 mg once weekly 0.2 mL 20 u 4 2 mg
Weeks 9–12 1 mg once weekly 0.4 mL 40 u 4 4 mg
Weeks 13–16 1.7 mg once weekly 0.68 mL 68 u 4 6.8 mg
Week 17 onward
per 4 weeks from here on		 2.4 mg once weekly 0.96 mL 96 u 4 9.6 mg
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About SemaglutideAbout This Peptide

Metabolic / Incretin
Also known as
GLP-1 receptor agonist
Class
Metabolic / Incretin
Route
Subcutaneous
Half-life
~7 days
Evidence tier
Clinical

The most extensively trialled compound in this database. Approved formulations follow a fixed escalation schedule to manage gastrointestinal tolerability; the figures below reflect the STEP obesity trial titration.

Buy Semaglutidethis peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Once-weekly semaglutide in adults with overweight or obesity (STEP 1) Wilding JPH, et al. New England Journal of Medicine, 2021
The pivotal 68-week obesity trial; source of the 2.4 mg maintenance dose and the escalation schedule.
Find on PubMed ↗
Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) Lincoff AM, et al. New England Journal of Medicine, 2023
Large cardiovascular outcomes trial; the strongest safety dataset at the 2.4 mg dose.
Find on PubMed ↗
Semaglutide 2.4 mg — pharmacokinetics and dose-response Overgaard RV, et al. Clinical Pharmacokinetics, 2021
Underpins the weekly cadence and the ~1-week half-life figure.
Find on PubMed ↗

Newest Studies — —

—
Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

More peptides

Browse the full catalogue, or jump to a neighbouring compound.

GHK-Cu

A copper-binding tripeptide present in human plasma, declining with age. The strongest evidence covers collagen synthesis, wound h…

Tirzepatide

A dual incretin agonist. SURMOUNT-1 established the 5/10/15 mg maintenance arms with a four-week-per-step escalation from 2.5 mg.…

All 71 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.